Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;114(1):186-194.
doi: 10.1111/ejh.14325. Epub 2024 Oct 12.

Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement

R Liévin  1   2 , B Burroni  3 , E Balducci  4 , P Palmic  3 , J Decroocq  1 , B Deau-Fischer  1 , P Franchi  1 , M Vignon  1 , J Zerbit  5 , A S Cottereau  6 , A Touzart  7   8 , P Villarese  4 , S Kaltenbach  4 , L Lhermitte  4 , V Asnafi  4 , D Bouscary  1 , L Willems  1
Affiliations

Biological Findings and Clinical Outcomes in Patients Treated With R-CHOP Plus High-Dose Methotrexate as First-Line Therapy in Large B-Cell Lymphoma With Testis Involvement

R Liévin et al. Eur J Haematol. 2025 Jan.

Abstract

Primary testicular lymphoma (PTL) is a rare occurrence of diffuse large B-cell lymphoma (DLBCL) that accounts for 1%-2% of all cases. Nodal DLBCL with testis involvement (DLBCL-T) and PTL are associated with poor prognosis, with high incidence of central nervous system relapse. Fifteen patients (median age 60 years) with PTL (n = 5) or DLBCL-T (n = 10) received high-dose methotrexate + R-CHOP. Overall, complete response (CR) rate was 73% and overall response rate 86%. With a 3.9-year median follow-up, 100% of patients with PTL had CR and none relapsed. On the contrary, 55% of DLBCL-T patients achieved CR among which only one was still in remission at the end of follow-up. Molecular parallels between PTL and Primary CNS Lymphoma (PCNSL) suggest shared origins, urging further research for tailored treatments and enhanced understanding of these lymphomas' biology.

Keywords: CNS relapse; DLBCL; methotrexate; testis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Swimmer plot of patient individual outcomes after initial R HD‐MTX CHOP therapy.
FIGURE 2
FIGURE 2
Molecular landscape in patients with DLBCL‐T or PTL.
See this image and copyright information in PMC

References

    1. Gundrum J. D., Mathiason M. A., Moore D. B., and Go R. S., “Primary Testicular Diffuse Large B‐Cell Lymphoma: A Population‐Based Study on the Incidence, Natural History, and Survival Comparison With Primary Nodal Counterpart Before and After the Introduction of Rituximab,” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 27, no. 31 (2009): 5227–5232. - PubMed
    1. Bobillo S., Joffe E., Lavery J. A., et al., “Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B‐Cell Lymphoma in the Rituximab Era,” Blood 137, no. 1 (2021): 39–48. - PMC - PubMed
    1. Swerdlow S. H., Campo E., Harris N. L., et al., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues WHO Classification of Tumours, vol. 2, 4th ed. (Lyon, France: International Agency for Research on Cancer, 2017).
    1. Alaggio R., Amador C., Anagnostopoulos I., et al., “The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms,” Leukemia 36, no. 7 (2022): 1720–1748. - PMC - PubMed
    1. Roschewski M., Phelan J. D., and Jaffe E. S., “Primary Large B‐Cell Lymphomas of Immune‐Privileged Sites,” Blood (2024), 10.1182/blood.2023020911. - DOI - PubMed

MeSH terms